Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example Input: Teva Pharmaceutical Industries Ltd’s rival migraine headache preventer is excluded on one list and patients can pay more for it in some cases on a second list, the note said. As with rival PBMs Express Scripts and CVS Health Corp, OptumRx’s lists of covered drugs, or formularies, cover tens of millions of consumers who receive their healthcare from employers and health insurers. About 39 million Americans suffer from migraine headaches, according to the Migraine Research Foundation, and global migraine drug sales could reach $8.7 billion by 2026, according to analytics firm GlobalData. OptumRx’s decision secures easier access to customers for Lilly’s Emgality at all three of the biggest PBMs - including CVS and Express Scripts - and gives Amgen’s Aimovig a leg up after CVS decided not to include it on its preferred drug list. Teva’s Ajovy only has preferred status at CVS, while Amgen also has it at Express Scripts, part of Cigna Corp.  “We are pleased that all three companies have chosen Emgality to be one of the preferred medications, making it accessible to even more patients suffering from migraine,” Lilly said in an emailed statement. Inclusion on a preferred drugs list by the largest PBMs and health insurers is critically important for sales of new medicines. Increasingly, PBMs are choosing a subset of treatments for their coverage list when there are multiple treatments that are considered equivalent. The three treatments, approved by the U.S. Food and Drug Administration last year, belong to a class of drugs called CGRP inhibitors that have proven effective in helping to prevent migraines. A Teva spokeswoman said the company is committed to increasing access to Ajovy regardless of formulary decisions and is still offering discounts that allow patients to pay nothing in some cases, regardless of insurance. “Since Ajovy injection launched in September, we have experienced strong demand and steady growth, and we continue discussions with payers,” the spokeswoman said. An Amgen spokeswoman said that the company was pleased with the decision and is committed to ensuring affordable access to its drug. Amgen, which shares Aimovig U.S. revenue with Novartis AG, earlier this week reported fourth-quarter sales of $95 million, nearly doubling Wall Street estimates. The OptumRx decision becomes effective Feb. 1. The OptumRx select formulary relegates Teva’s drug to a lower access level that would typically require a higher out-of-pocket cost, it said. PBMs typically extract discounts from drugmakers in return for favorable placement on their preferred list of covered drugs, such as through a low co-payment, or coinsurance payment, for their members. All three migraine drugs have a list price of $575 a month, or $6,900 a year. Those prices do not reflect the rebates and discounts to PBMs, who design and negotiate benefits for employers and insurers. All three drugmakers are providing a limited duration supply of the new drugs at no cost directly to patients in addition to other assistance programs. Amgen’s Aimovig was first-to-market from the new class. But the rivals from Teva and Lilly followed soon after. The three large PBMs together cover the majority of the more than 150 million Americans who receive benefits through their employers. Their clients, including insurers and corporations, may choose not to follow a PBM’s recommendations on coverage, but that typically would cost more. Amgen shares were off 28 cents at $186.63, Lilly was up nearly 1 percent at $120.90 and Teva shares traded in New York  were down nearly 1 percent at $19.69.
Example Output: Exclusive: Top U.S. insurer to cover Amgen, Eli Lilly migraine drugs, exclude Teva.

Example Input: The Trump administration has called for 30 days of measures, including staying at least six feet away from other people, that have upended American life as most people stay isolated at home, shuttering schools and closing businesses through at least the end of April, with some states continuing certain closures through May and June. Dr. Anthony Fauci, the head of the National Institute of Allergy and Infectious Diseases, said such steps must continue but that there are hopeful signs they are working. “If in fact we are successful, it makes sense to at least plan what a re-entry into normality would look like. That doesn’t mean we’re going to do it right now, but it means we need to be prepared to ease into that,” Fauci, a member of the White House coronavirus task force, told Fox News in an interview. Fauci and other public health experts have said the strict measures are needed to control the fast-spreading and potentially fatal disease that has already led to about 400,000 confirmed COVID-19 U.S. cases and nearly 13,000 deaths, even as the shutdowns have roiled the U.S. economy. Dr. Deborah Birx, another task force member, said isolation measures must continue for now or else the country could risk a repeated spike despite the allure of warmer spring weather. “What’s really important is that people don’t turn these early signs of hope into releasing from the 30 days to stop the spread. It’s really critical,” she told NBC News’ “Today” program. “If people start going out again and socially interacting, we could see a really acute second wave.”  Asked if 30-day distancing practices would be enough or that steps might have to continue longer, she said officials were looking at each area of the country differently as they weigh the data. “Clearly, there are metro areas that are struggling,” Birx said.
Example Output: U.S. planning ways to 'ease' back to normal if virus efforts work: Fauci.

Example Input: The bill passed both houses of the New Jersey legislature with strong bipartisan support and was sitting on Chistie’s desk on Friday but the Republican presidential hopeful would not indicate his intentions. The legislation would completely prohibit smoking inside all state, county and municipal parks. Public beaches would also be smoke-free, though local officials can opt to save 15 percent of beach land as a designated smoking section. “This is definitely groundbreaking,” said Karen Blumenfeld, the executive director of Global Advisors on Smokefree Policy, a proponent of the New Jersey bill. “We would be the first state to impose such a wide ban in all public outdoor spaces and the legislation will continue the trend of New Jersey being a model for other jurisdictions’ anti-smoking policies,” she said. Smoking is the leading cause of preventable death in the United States, and second-hand smoke exposure has been linked to asthma, lung cancer, and stroke, according to the Centers for Disease Control and Prevention. Supporters say the ban will allow New Jersey residents and visitors to enjoy parks and beaches without the distraction of wafting cigarette smoke and would drastically reduce litter, fire risks and children’s exposure to smoking. “No one needs to sit in an ashtray when ‎enjoying the beach,” state Senator Joseph Vitale, a sponsor of the bill, told local media. Blumenfeld said the measure has a “critical mass” of support in the state. But some residents said the measure would trample on personal liberties. “I don’t think the government needs to be involved,” said Bryan Adamson, 32, of Blairstown. “As a smoker I use common sense and respect for the environment and those around me,” he said. Others said it was time to put an end to the outdoors as a  last sanctuary for those who choose to light up. “Even when I smoked and was on the beach next to a smoker I would be frustrated because frankly I don’t want to be stuck around it if I don’t have to be,” said Lauren DiGenova, 26, of Waldwick. New Jersey has some of the strictest anti-smoking policies in the country. It was the first state to prohibit smoking in college dormitories in 2005, Blumenfeld said. A year later, Trenton banned indoor smoking in bars and restaurants. More than 200 New Jersey cities, towns and boroughs have already passed their own restrictions on cigarette and tobacco use in parks and beaches. The legislation would cover outdoor public spaces across the state. Offenders would face a $250 fine for the first offense, $500 for the second and $1,000 for each additional citation. Christie’s office would not say where the governor stood on the bill.
Example Output:
New Jersey may be first state to ban smoking on beaches, in parks.